Correlation Between Fate Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fate Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on Fate Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and Molecular Partners.
Diversification Opportunities for Fate Therapeutics and Molecular Partners
-0.31 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Fate and Molecular is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Fate Therapeutics and Molecular Partners
Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Fate Therapeutics is 1.06 times less risky than Molecular Partners. The stock trades about -0.14 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 462.00 in Molecular Partners AG on September 25, 2024 and sell it today you would earn a total of 82.00 from holding Molecular Partners AG or generate 17.75% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Fate Therapeutics vs. Molecular Partners AG
Performance |
Timeline |
Fate Therapeutics |
Molecular Partners |
Fate Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Fate Therapeutics and Molecular Partners
The main advantage of trading using opposite Fate Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.Fate Therapeutics vs. Atara Biotherapeutics | Fate Therapeutics vs. Sana Biotechnology | Fate Therapeutics vs. Caribou Biosciences | Fate Therapeutics vs. Arcus Biosciences |
Molecular Partners vs. Fate Therapeutics | Molecular Partners vs. Caribou Biosciences | Molecular Partners vs. Karyopharm Therapeutics | Molecular Partners vs. X4 Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Complementary Tools
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |